Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

This is a single institution, single arm, Phase II study examining the clinical efficacy of
an allogeneic GM-CSF secreting myeloma vaccine in combination with lenalidomide. Fifteen (15)
patients enrolled in the study must have two disease measurements (including the last one)
consistent with a near complete remission (M-spike negative with persistence of
immunofixation) per criteria for response in a 6 month period. Patients will continue on the
dose of lenalidomide they were on prior to being enrolled but will need to discontinue
steroids for at least 4 weeks. Patients will receive 4 vaccinations on day 14(+/-3 days) of
cycles 1, 2, 3 and 6 from enrollment that will include both the myeloma vaccine as well as
Prevnar.

Inclusion Criteria:

- Myeloma eligibility criteria are the following:

- sustained near complete remission (nCR) for 4 months defined as no measurable
M-spike and a positive immunofixation

- early biochemical relapse as manifest by going from a true CR (immunofixation
negative) to a nCR (immunofixation positive) at any time

- conversion from a nCR to the appearance of a monoclonal spike in the serum not
greater than 0.3mg/dL

- age 18 years and older

- Eastern Cooperative Oncology Group performance scores 0-2

- History of measurable serum or urine M protein or free light chains

- Life expectancy greater than 12 months

- Corrected serum calcium < 11 mg/dL, and no evidence of symptomatic hypercalcemia

- Serum creatinine< 2

- Absolute Neutrophil Count >1000

- Platelet >100,000

- Total bilirubin less than or equal to 1.5 x Upper limit of normal

- Aspartate aminotransferase and Alanine transaminase less than or equal to 3 x Upper
limit of normal

- Negative pregnancy test if applicable

- Ability to comprehend and have signed the informed consent.

- Disease free of prior malignancies for < 5 years with exception of currently treated
basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix
or breast.

- All study participants must be registered into the mandatory RevAssist® program, and
be willing and able to comply with the requirements of RevAssist®.

- Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
and again within 24 hours of prescribing lenalidomide (prescriptions must be filled
within 7 days) and must either commit to continued abstinence from heterosexual
intercourse or begin TWO acceptable methods of birth control, one highly effective
method and one additional effective method AT THE SAME TIME, at least 28 days before
she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men
must agree to use a latex condom during sexual contact with a FCBP even if they have
had a successful vasectomy. See Appendix: Risks of Fetal Exposure, Pregnancy Testing
Guidelines and Acceptable Birth Control Methods.

- Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients
intolerant to aspirin may use warfarin or low molecular weight heparin).

Exclusion Criteria:

- Disease progression after stopping corticosteroids as defined as the appearance of an
M-spike >0.5g/dL

- Patients with a known diagnosis of POEMS syndrome, plasma cell leukemia, non-secretory
myeloma and amyloidosis.

- HIV disease, active infection requiring treatment with antibiotics, anti-fungal or
anti-viral agents within 2 weeks of enrollment would be excluded from the study.

- Patients who have participated in any clinical trial, within four weeks prior to
registration on this trial, which involved an investigational drug.

- History of an active malignancy other than myeloma

- Autoimmune disease requiring active treatment.

- Known contra-indication to any component of Prevnar 13 including the diphtheria
toxoid-containing vaccine.

- History of latex allergy

- History of an autologous stem cell transplant within the past 12 months or less

- History of an allogeneic transplant